Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioCryst ( (BCRX) ) just unveiled an announcement.
On June 27, 2025, BioCryst Pharmaceuticals announced the sale of its European ORLADEYO business to Neopharmed Gentili for up to $264 million. The transaction will allow BioCryst to eliminate its remaining term debt, saving approximately $70 million in future interest payments, and is expected to leave the company with $700 million in cash by the end of 2027. This strategic move aligns with BioCryst’s goal of enhancing profitability and sustaining growth, while Neopharmed Gentili aims to strengthen its position in the European specialty pharmaceutical market.
The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s strong technical momentum and positive earnings call drive the score higher, despite financial instability. Regulatory successes and strategic leadership changes also support the score, but persistent net losses and negative equity pose significant risks.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals is a global biotechnology company focused on developing oral small-molecule and protein therapeutics for rare diseases, including hereditary angioedema. The company is known for its expertise in structure-guided drug design and has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor.
Average Trading Volume: 4,543,229
Technical Sentiment Signal: Buy
Current Market Cap: $2.04B
See more data about BCRX stock on TipRanks’ Stock Analysis page.